Pulse Biosciences Files 8-K
Ticker: PLSE · Form: 8-K · Filed: Oct 24, 2025 · CIK: 1625101
| Field | Detail |
|---|---|
| Company | Pulse Biosciences, Inc. (PLSE) |
| Form Type | 8-K |
| Filed Date | Oct 24, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, SEC
TL;DR
Pulse Biosciences filed an 8-K on 10/24/25, likely containing routine financial updates.
AI Summary
On October 24, 2025, Pulse Biosciences, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events detailed in the provided text. The company, formerly known as Electroblate, Inc., is incorporated in Delaware and headquartered in Hayward, California.
Why It Matters
This 8-K filing indicates Pulse Biosciences is submitting required documentation to the SEC, which could include updates on financial status or other corporate events.
Risk Assessment
Risk Level: low — The filing appears to be routine and does not disclose any immediate material adverse events.
Key Players & Entities
- Pulse Biosciences, Inc. (company) — Registrant
- October 24, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 46-5696597 (ein) — IRS Employer Identification No.
- 601 Brickell Key Drive, Suite 1080 Miami , Florida 33131 (address) — Address of Principal Executive Offices
- 510 - 906-4600 (phone_number) — Registrant's Telephone Number
- Electroblate, Inc. (company) — Former Company Name
- 3957 POINT EDEN WAY HAYWARD CA 94545 (address) — Business Address
FAQ
What is the primary purpose of this 8-K filing by Pulse Biosciences, Inc. on October 24, 2025?
The filing is a Current Report (Form 8-K) pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, reporting 'Other Events' and 'Financial Statements and Exhibits'.
When was Pulse Biosciences, Inc. incorporated and in which state?
Pulse Biosciences, Inc. was incorporated in Delaware.
What is the principal executive office address for Pulse Biosciences, Inc. as listed in the filing?
The address of the Principal Executive Offices is 601 Brickell Key Drive, Suite 1080, Miami, Florida 33131.
What were the former names of Pulse Biosciences, Inc. mentioned in the filing?
The filing mentions former names including Pulse Biosciences, Inc. (with a name change date of 20151210) and Electroblate, Inc. (with a name change date of 20141113).
What is the IRS Employer Identification Number (EIN) for Pulse Biosciences, Inc.?
The IRS Employer Identification Number (EIN) for Pulse Biosciences, Inc. is 46-5696597.
Filing Stats: 504 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2025-10-24 08:54:21
Key Financial Figures
- $0.001 — nge on Which Registered Common stock , $0.001 par value per share PLSE The Nasdaq
Filing Documents
- plse20251024_8k.htm (8-K) — 25KB
- ex_875677.htm (EX-99.1) — 13KB
- 0001437749-25-031680.txt ( ) — 169KB
- plse-20251024.xsd (EX-101.SCH) — 3KB
- plse-20251024_def.xml (EX-101.DEF) — 11KB
- plse-20251024_lab.xml (EX-101.LAB) — 15KB
- plse-20251024_pre.xml (EX-101.PRE) — 11KB
- plse20251024_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events. On October 24, 2025, Pulse Biosciences, Inc. (the "Company") issued a press release announcing the enrollment of the first patient in its NANOCLAMP AF clinical trial, a single-arm, prospective multicenter study designed to demonstrate the safety and effectiveness of the Company's nPulse Cardiac Surgical System for the treatment of atrial fibrillation in concomitant surgical procedures. The successful first procedure was completed at St. Helena Hospital in St. Helena, California . A copy of the press release related to the matters set forth herein is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release issued by Pulse Biosciences, Inc. dated October 24, 2025 - Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PULSE BIOSCIENCES, INC. Date: October 24, 2025 By: /s/ Paul A. LaViolette Paul LaViolette Chief Executive Officer (Principal Executive Officer)